7 September 2018 - - US-based biomedical products company Cerus Corp. (NASDAQ: CERS) has appointed Timothy L. Moore to its board of directors, the company said.

Moore, who currently serves as executive vice president, technical operations for Kite, a Gilead company, brings over three decades of experience in engineering, manufacturing, and technical operations in the biopharmaceutical industry.

Prior to his current position at Kite where he has led the global manufacturing effort for the launch of Kite's revolutionary Yescarta product, Moore served 12 years in various engineering, supply chain and manufacturing leadership roles at Genentech, most recently as senior vice president and head of global technical operations, biologics unit.

Previously in his career, Moore held senior manufacturing, operations, and engineering positions at CSL Ltd, Armour Pharmaceuticals, and Merck.

Cerus is a biomedical products company focused in the field of blood transfusion safety.

The Intercept Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a range of pathogens such as viruses, bacteria and parasites that may be present in donated blood.

The nucleic acid targeting mechanism of action of the Intercept treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue.

Cerus currently markets and sells the Intercept Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.

The Intercept Red Blood Cell system is in clinical development.